461
SERUM HBCRAG PROFILES IN CHRONIC HEPATITIS B
PATIENTS TREATED WITH FIRST-LINE ORAL ANTIVIRAL
THERAPY
Lung Yi Mak1, Danny Ka Ho Wong1,2, Wai-Kay Seto1,2, James
Fung1,2, Ching Lung Lai2,3 and Man Fung Yuen1,3, (1)Medicine,
The University of Hong Kong, (2)State Key Laboratory of Liver
Research, The University of Hong Kong, (3)The University of
Hong Kong, Hong Kong
Background: Serum hepatitis B core-related antigen
(HBcrAg) is a potential surrogate marker for intra-hepatic
covalently-closed circular DNA in chronic hepatitis B (CHB)
We aimed to study the profiles of serum HBcrAg in CHB
patients treated with first-line oral nucleos(t)ide analogues
(NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF)
or tenofovir alafenamide (TAF) Methods: Serum HBcrAg
was measured in 264 NA-treated CHB patients (ETV: TDF:
TAF = 197: 30: 37) using the Lumipulse G HBcrAg assay in a
Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan) with
a lower detection limit of 100 units per milliliter (U/ml) The
values of HBcrAg were log transformed and were expressed
in log U/mL Serum HBcrAg levels were measured at baseline,
48-week and 96-week of NA therapy Results: Among the
264 patients, 130 (49 2%) were hepatitis B e antigen (HBeAg)
positive In this interim report, HBcrAg level measurements
were completed for all 3 groups of patients at baseline and
week 48 and for TDF and TAF treated patients at week 96 All
3 first-line NAs led to significant decline of serum HBcrAg at
48-week compared to baseline (ETV: 1.97 vs. 3.02, TDF: 2.88
vs. 4.49, and TAF: 3.00 vs. 4.36, respectively; all p <0.001).
For TDF and TAF, further decline of HBcrAg was observed at
96-week compared to 48-week (TDF: 2.09 vs. 2.88, and TAF
1.89 vs. 3.00, respectively; both p<0.01) [figure]. However,
when only HBeAg-negative patients were analyzed, the
drop in HBcrAg at 96-week compared to 48-week was not
significant for both TDF and TAF treated patients (0.62 vs.
1.08 and 0.56 vs. 0.80, respectively; both p>0.05). There
were no significant differences for the magnitude of HBcrAg
decline at 48-week between the 3 different types of NAs (ETV:
1.088; TDF: 1.437; TAF: 1.318; p>0.05 for all 3 comparisons).
Similarly, TDF and TAF produced no significant differences in
the magnitude of HBcrAg decline at 96-week (2 20 vs 1 74,
p>0.05). Conclusion: The 3 first-line NAs showed similar
potencies in suppression of viral activity upon 1 year duration
of therapy. The lack of significant drop of HBcrAg in HBeAgnegative
patients reflects the limited utility of this marker in
HBeAg-negative phase. 作者: StephenW 时间: 2019-10-26 16:05